12 Month Price Forecast For HIMS
Distance to HIMS Price Forecasts
HIMS Price Momentum
๐ค Considering Hims & Hers (HIMS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 3:49 PM UTC
HIMS Analyst Ratings & Price Targets
Based on our analysis of 20 Wall Street analysts, HIMS has a neutral consensus with a median price target of $24.50 (ranging from $18.00 to $38.00). Currently trading at $60.47, the median forecast implies a -59.5% downside. This outlook is supported by 5 Buy, 6 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Maria Ripps at Canaccord Genuity, projecting a 37.2% downside. Conversely, the most conservative target is provided by Allen Lutz at B of A Securities, suggesting a 70.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HIMS Analyst Consensus
HIMS Price Target Range
Latest HIMS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HIMS.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 10, 2025 | Citigroup | Daniel Grosslight | Sell | Downgrade | $25.00 |
Jan 7, 2025 | BTIG | David Larsen | Buy | Initiates | $35.00 |
Jan 6, 2025 | Needham | Ryan MacDonald | Buy | Maintains | $31.00 |
Jan 6, 2025 | Piper Sandler | Korinne Wolfmeyer | Neutral | Maintains | $24.00 |
Dec 17, 2024 | Morgan Stanley | Craig Hettenbach | Overweight | Initiates | $42.00 |
Dec 2, 2024 | Canaccord Genuity | Maria Ripps | Buy | Maintains | $38.00 |
Nov 20, 2024 | TD Cowen | Buy | Reiterates | $0.00 | |
Nov 14, 2024 | B of A Securities | Allen Lutz | Underperform | Downgrade | $18.00 |
Nov 8, 2024 | TD Cowen | Jonna Kim | Buy | Maintains | $28.00 |
Nov 6, 2024 | Deutsche Bank | George Hill | Hold | Maintains | $27.00 |
Nov 5, 2024 | Piper Sandler | Korinne Wolfmeyer | Neutral | Reiterates | $21.00 |
Nov 5, 2024 | Canaccord Genuity | Maria Ripps | Buy | Maintains | $28.00 |
Oct 21, 2024 | B of A Securities | Michael Cherny | Buy | Maintains | $25.00 |
Oct 14, 2024 | B of A Securities | Michael Cherny | Buy | Maintains | $23.00 |
Sep 13, 2024 | B of A Securities | Michael Cherny | Buy | Maintains | $20.00 |
Aug 22, 2024 | Needham | Ryan MacDonald | Buy | Initiates | $24.00 |
Aug 7, 2024 | Deutsche Bank | George Hill | Hold | Maintains | $23.00 |
Aug 6, 2024 | Piper Sandler | Korinne Wolfmeyer | Neutral | Reiterates | $18.00 |
Jul 18, 2024 | Truist Securities | Jailendra Singh | Hold | Maintains | $23.00 |
Jul 11, 2024 | TD Cowen | Jonna Kim | Buy | Maintains | $25.00 |
Stocks Similar to Hims & Hers Health, Inc.
The following stocks are similar to Hims & Hers based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Hims & Hers Health, Inc. (HIMS) Financial Data
Hims & Hers Health, Inc. has a market capitalization of $13.21B with a P/E ratio of 137.4x. The company generates $1.24B in trailing twelve-month revenue with a 8.2% profit margin.
Revenue growth is +77.1% quarter-over-quarter, while maintaining an operating margin of +5.6% and return on equity of +26.3%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Hims & Hers Health, Inc. (HIMS) Company Overview
About Hims & Hers Health, Inc.
Telehealth platform connecting consumers to healthcare professionals.
The company operates a telehealth platform that allows consumers to access licensed healthcare professionals and purchase various health and wellness products directly through its websites and mobile application. It generates revenue by offering both prescription and non-prescription products, including medication subscriptions and ongoing care services, targeting markets like general wellness, sexual health, skincare, and hair care.
Hims & Hers Health, Inc. provides curated wellness products across several categories, including supplements and skincare. The company also has a wholesale distribution model, supplying health and wellness products through various partners. Based in San Francisco, California, it serves customers in the U.S., U.K., and internationally.
Company Information
Sector
Consumer Defensive
Industry
Household & Personal Products
Employees
1,046
CEO
Mr. Andrew Dudum
Country
United States
IPO Year
2021
Website
www.forhims.comHims & Hers Health, Inc. (HIMS) Latest News & Analysis
Why Hims & Hers Terrifies Big Pharma
3 days agoHims & Hers launched a Super Bowl ad, facing pushback from pharmaceutical companies and pharmacists, indicating its strong disruptive potential in the market.
Hims & Hers facing pushback on its Super Bowl ad indicates strong market disruption potential, suggesting competitive threats to traditional pharmaceutical models, which could impact investor sentiment.
Hims & Hers options trade allows for a potential $410 return or acquisition of stock at a 17% discount, aiming for either option to benefit investors.
The option trade indicates potential profitability through premium income or acquiring stock at a discount, signaling positive sentiment and strategic opportunities in Hims & Hers.
Hims & Hers stock gained 350% in 2024, driven by revenue growth and positive cash flow. The company has $250M cash, no debt, and plans to expand its subscriber base and revenue per subscriber.
Hims & Hers' 350% stock gain, strong cash position, and no debt indicate robust financial health, while growth potential in personalized solutions suggests further revenue upside.
Supply shortages and high costs of GLP-1 weight loss drugs are opening the market for compounded treatments, which can be offered due to FDA drug shortage listings.
The entry of compounded GLP-1 treatments could alter market dynamics, impacting pricing and competition, which may affect shares of pharmaceutical companies involved in weight loss drugs.
Hims & Hers Super Bowl ad sparks controversy
5 days agoHims & Hers faces controversy regarding its Super Bowl ads, as discussed by CNBC's Brandon Gomez on 'Squawk on the Street.'
Controversy around Hims & Hers Super Bowl ads could impact brand perception and sales, affecting stock performance and investor confidence.
Hims & Hers faces controversy regarding its Super Bowl ad, as analyzed by CNBC's Brandon Gomez. Investors should monitor public reaction and potential brand impact.
The controversy may impact Hims & Hers' brand perception and customer sentiment, potentially affecting stock performance and future marketing strategies.
Frequently Asked Questions About HIMS Stock
What is Hims & Hers Health, Inc.'s (HIMS) stock forecast for 2025?
Based on our analysis of 20 Wall Street analysts, Hims & Hers Health, Inc. (HIMS) has a median price target of $24.50. The highest price target is $38.00 and the lowest is $18.00.
Is HIMS stock a good investment in 2025?
According to current analyst ratings, HIMS has 5 Buy ratings, 6 Hold ratings, and 2 Sell ratings. The stock is currently trading at $60.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for HIMS stock?
Wall Street analysts predict HIMS stock could reach $24.50 in the next 12 months. This represents a -59.5% decrease from the current price of $60.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Hims & Hers Health, Inc.'s business model?
The company operates a telehealth platform that allows consumers to access licensed healthcare professionals and purchase various health and wellness products directly through its websites and mobile application. It generates revenue by offering both prescription and non-prescription products, including medication subscriptions and ongoing care services, targeting markets like general wellness, sexual health, skincare, and hair care.
What is the highest forecasted price for HIMS Hims & Hers Health, Inc.?
The highest price target for HIMS is $38.00 from Maria Ripps at Canaccord Genuity, which represents a -37.2% decrease from the current price of $60.47.
What is the lowest forecasted price for HIMS Hims & Hers Health, Inc.?
The lowest price target for HIMS is $18.00 from Allen Lutz at B of A Securities, which represents a -70.2% decrease from the current price of $60.47.
What is the overall HIMS consensus from analysts for Hims & Hers Health, Inc.?
The overall analyst consensus for HIMS is neutral. Out of 20 Wall Street analysts, 5 rate it as Buy, 6 as Hold, and 2 as Sell, with a median price target of $24.50.
How accurate are HIMS stock price projections?
Stock price projections, including those for Hims & Hers Health, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.